{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sidiras P"],"funding":["Fonds Erasme pour la Recherche Médicale’","Radio-télévision belge de la Communauté française (RTBF)","Fonds de la recherche scientifique-FNRS","King Baudouin Foundation"],"pagination":["2826-2834"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9258537"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["61(7)"],"pubmed_abstract":["<h4>Objectives</h4>Anti-carbamylated protein antibodies (anti-CarPAs) are present in RA sera and have been associated with erosive disease. The exact targets of anti-CarPAs in vivo are currently not well known; we used a proteomic approach on serum and SF of RA patients to assess the human carbamylome and to identify carbamylated autoantigens as potential biomarkers in early RA.<h4>Methods</h4>Mass spectrometry was performed on SF and serum from RA patients. Carbamylated proteins present in both sample types were selected as candidate autoantigens for the establishment of ELISAs. A cohort of early RA patients was tested for positivity for specific anti-CarPAs.<h4>Results</h4>Eleven novel carbamylated proteins were identified, and five were selected as potential autoantigens for detection o"],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Human carbamylome description identifies carbamylated α2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis."],"pmcid":["PMC9258537"],"funding_grant_id":["CAP48"],"pubmed_authors":["Lechanteur J","Imbault V","Sidiras P","Durez P","Rasschaert J","Sokolova T","Gangji V","Communi D"],"additional_accession":[]},"is_claimable":false,"name":"Human carbamylome description identifies carbamylated α2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis.","description":"<h4>Objectives</h4>Anti-carbamylated protein antibodies (anti-CarPAs) are present in RA sera and have been associated with erosive disease. The exact targets of anti-CarPAs in vivo are currently not well known; we used a proteomic approach on serum and SF of RA patients to assess the human carbamylome and to identify carbamylated autoantigens as potential biomarkers in early RA.<h4>Methods</h4>Mass spectrometry was performed on SF and serum from RA patients. Carbamylated proteins present in both sample types were selected as candidate autoantigens for the establishment of ELISAs. A cohort of early RA patients was tested for positivity for specific anti-CarPAs.<h4>Results</h4>Eleven novel carbamylated proteins were identified, and five were selected as potential autoantigens for detection o","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-25T20:59:43.067Z","creation":"2022-07-23T08:44:53.935Z"},"accession":"S-EPMC9258537","cross_references":{"pubmed":["34788409"],"doi":["10.1093/rheumatology/keab838"]}}